Year : 2018 | Volume
: 11 | Issue : 2 | Page : 89--97
Exploring dynamic biomedical algorithm of Eurycoma longifolia Jack and its bioactive phytochemicals: A review of pharmacokinetic and pharmacodynamic implications and future prospects
Hnin Ei Thu1, Zahid Hussain2, Isa Naina Mohamed1, Ahmad Nazrun Shuid1,
1 Department of Pharmacology, Faculty of Medicine, University Kebangsaan Malaysia (The National University of Malaysia), Jalan Yaacob Latif 56000, Cheras, Malaysia
2 Department of Pharmaceutics, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, Bandar Puncak Alam 42300, Selangor, Malaysia
Dr. Ahmad Nazrun Shuid
Department of Pharmacology, Faculty of Medicine, University Kebangsaan Malaysia, Jalan Yaacob Latif 56000, Cheras
Eurycoma longifolia Jack (E. longifolia) is a well-recognized traditional herbal medicine that offers a wide dynamic range of biomedical applications including anti-osteoporotic, anticancer, anti-proliferative, anti-malarial, antimicrobial, antioxidant, aphrodisiac, anti-inflammatory, anxiolytic, anti-diabetic, anti-rheumatism and anti-ulcer properties. This review aims to overview the pharmacokinetic and a pharmacodynamic algorithm of E. longifolia and its bioactive components. Analysis of pharmacokinetic profile revealed that E. longifolia exhibit higher bioavailability, high volume of distribution, slow elimination rate, and does not show inhibitory effects on cytochrome P450 isoenzymes. E. longifolia has been used, alone or in combination with other pharmacological agents, in the form of crude extracts, standard extracts, or decoctions of different plant parts (i.e., herbs, shrubs, stem, leaves, and roots) for the treatment of various ailments in animals and humans. Among various bioactive constituents, eurycomanone has been found to be the most remarkable, super-stable, versatile, and most potent phytochemical (isolated or extracted from root extracts) against various types of animals and human diseases. Based on its well-established pharmacokinetic and pharmacodynamic profiles, we suggested that E. longifolia can be a well-accepted complementary and alternative medicine for the treatment of different types of human ailments.
|How to cite this article:|
Thu HE, Hussain Z, Mohamed IN, Shuid AN. Exploring dynamic biomedical algorithm of Eurycoma longifolia Jack and its bioactive phytochemicals: A review of pharmacokinetic and pharmacodynamic implications and future prospects.Asian Pac J Trop Med 2018;11:89-97
|How to cite this URL:|
Thu HE, Hussain Z, Mohamed IN, Shuid AN. Exploring dynamic biomedical algorithm of Eurycoma longifolia Jack and its bioactive phytochemicals: A review of pharmacokinetic and pharmacodynamic implications and future prospects. Asian Pac J Trop Med [serial online] 2018 [cited 2020 Jan 24 ];11:89-97
Available from: http://www.apjtm.org/text.asp?2018/11/2/89/225015
Eurycoma longifolia Jack (E. longifolia), a potent medicinal herb in the family of Simaroubaceae, is known locally as tongkat ali in Malaysia, Pasak bumi in Indonesia, Tung saw in Thailand, and cay ba bihn in Vietnam. E. longifolia has gained remarkable recognition among various ethnic groups in Malaysia, China and South Africa due to its excellent pharmacological activities. Various parts of E. longifolia including roots, stem, and leaves have shown broad range of pharmacological activities including aphrodisiac, anti-malarial, antibacterial, anti-inflammatory, anxiolytic, anti-diabetic, anti-ulcer, anti-rheumatic, anticancer, and anti-osteoporotic activities,.
The pharmacokinetic profile of E. longifolia demonstrated that E. longifolia and its phytochemicals showed poor absorption after oral administration and low bioavailability. However, the plasma volume distribution of E. longifolia and its phytochemicals is greatly high which suggests that they are well-distributed in various tissues.
The administration of E. longifolia and its phytochemicals does not stimulate or down-regulate hepatic enzymes [cytochrome P450 (CYP) isoforms].
Bioactivity guided fractionation of E. longifolia and its medicinally active constitutents demonstrated that different parts of plant and its various phytochemicals exhibit varied pharmcodynamic response against various types of diseases. The strongest anti-osteoporotic activity of E. longifolia is exhibited by root extracts compared to the other parts of this plant. It is evident from an a wide range of in vivo and in vitro studies that the antiosteporotic activity of E. longifolia is due to its remarkable pro-androgenic effects which in turn improve bone formation and reduce bone resorption. The multi-dimentional pharmacodynamic spectrum of E. longifolia has also been evident from its well-recognized traditional use to improve male and female sexual well-being. Recently, Thu et al. has written an excellent systematic review in which they have critically analysed the excellent ability of E. longifolia and its phytomedicines in improving penile erection, male fertility and sexual libido due to their ability to improve synthesis of testosterone in the body.
Similarly, numerous studies evidenced that the aqueous, methanolic, ethanolic or butanolic extract of E. longifolia and various bioactive compounds have shown promising anti-proliferative and cytotoxic effects against various human cancer cell lines including liver carcinoma (HepG2), gastric carcinoma (MGC-803 and BGC-823 cells), intestinal cancers (HT-29 and LOVO cells), malignant melanoma (HM3KO), cervical carcinoma (Hela), human ovarian carcinoma (CaOV-3 and A-2780), breast cancers (MCF-7), and lung carcinoma (A-549 cells). Among various phytochemicals, eurycomanone showed highest anticancer efficacy and the mechanism of cytotoxicity is the induction of apoptosis (programmed cell death) via the up-regulation of the expression of p53 (a tumor suppressor protein). Phytochemical screening of various types of extracts from different parts (roots, stem, and leaves) of E. longifolia also displayed a dose-dependent antibacterial, antiprotozoal, and antifungal activities. It has also been explored that among various phytochemicals, eurycomanone from the root extract of E. longifolia exhibited strongest antimicrobial and antiplasmodial activities. There is no consensus for the superior efficacy of a specific type of plant part, extract type, and type of phytochemical for the anti-diabetic, anti-inflammatory, analgesic, and anti-ulcer effects. In the present review, we have overviewed a wide dyananic pharmacological spectrum of E. longifolia and its phytochemicals as well as their pharmacokinetic profile.
2. Pharmacokinetic considerations
Low et al. studied the pharmacokinetic profile of E. longifolia following an oral administration in animals and compared the results with intravenous administration. They demonstrated that E. longifolia showed lower absorption rate, Cmax (maximum plasma concentration), Tmax (time to achieve maximum plasma concentration), and bioavailability compared to intravenous route.
They further demonstrated that following an oral administration, Cmax and Tmax values were (0.33±0.03) μg/mL and (4.40±0.98) h, respectively.
Low et al. has also measured the volume of distribution of active constituents of E. longifolia. The volume of distribution of E. longifolia was calculated to be (0.68±0.30) L/kg which showed that E. longifolia is well-distributed into the extravascular fluids.
There is no consensus regarding the effect of E. longifolia and its phytochemcals on various isoforms of hepatic enzymes. Pan et al. demonstrated that E. longifolia and its phytochemcials did not show inhibitory or stimulatory effects on various CYP isoforms including CYP3A4, CYP2C8, CYP1A2, CYP2A6, CYP2C19, CYP2E1 and CYP2C9. It means that E. longifolia and its phytochemical have no drug-drug interactions in the context of metabolism. However, on the other hand, Han and co-workers revealed a dose-dependent inhibitory effects of E. longifolia and its phytochemicals on CYP2A6, CYP1A2, and CYP2C19 isozymes of P450 systems.
In an animal study, Low et al. have estimated the rate of excretion of E. longifolia and its active medicial components following an intravenous injection. They measured the mean excretion rate constant and clearance of (0.88±0.19)/h and (0.39±0.08) L/(h•kg), respectively.
Low et al. have also estimated the half-life of E. longifolia and its phytochemcials. They suggested that half-life of E. longifolia is slightly longer than its phytochemicals (eurycomanone). They estimated that half-life of E. longifolia was measured to be (0.75±0.25) h compared to (0.35±0.04) h for euyrocmanone due to lower elimination rate. The same group of scientists also reported that half-life of eurycomanone was estimated to be (1.00±0.26) h.
3. Pharmacodynamic consideration
Phytochemical screening of various types of extracts (methanolic, ethyl acetate, and n-butanolic) from different parts (roots, stem, and leaves) of E. longifolia have displayed a broad range of pharmacological activities including anti-osteoporotic, aphrodisiac anticancer, antimicrobial, anti-malarial, antioxidant, anti-inflammatory, anxiolytic, anti-diabetic, and anti-ulcer.
3.1. Anti-osteoporotic effects of E. longifolia
Osteoporosis is a bone disease characterised by a decreased bone density and weaker and porous bones that results in frequent bone fractures. In older males, it is the main cause of morbidity and mortality. It is estimated that approximately 2 million men in the United States suffer from this bone disorder. Worldwide, 1/3 women and 1/5 men over 50 experience osteoporotic fractures.
Numerous studies have shown that E. longifolia exhibits promising ability in treating male osteoporosis and reduce bone fractures by up-regulation of bone formation and down-regulation of bone resorption. Shuid et al. demonstrated that E. longifolia supplementation to orchidectomised rats maintain bone calcium levels and prevent bone mineral loss and therefore has the potential to be used as an alternative treatment for androgen deficient osteoporosis. The anti-osteporotic activity of E. longifolia is associated with enhanced biosynthesis of androgen hormones. Due to these pro-androgenic properties of E. longifolia, it is able to stimulate osteoblastic proliferation and differentiation, resulting in increased bone formation rate. High levels of testosterone and estrogen may also exert proapoptotic effects on osteoclasts, reducing the bone resorptive activity. This bone health promoting effect of E. longifolia appeals for its regular supplementation to avoid bone loss and improve bone health.
Oxidative stress is anothoer predator of bones that may stimulate bone loss. An imblance between the synthesis of free radicals (reactive oxygen species) and body scavenging ability may result in bone and extracellular tissue damage. The strong anti-osteoporotic efficacy of E. longifolia is due to its storong antioxidant capacity which reduce production of free radicals and thus alleviate oxidative stress. Moreover, according to Tambi and Kamarul, E. longifolia contains high concentrations of superoxide dismutase, an antioxidantd defense that plays an important role in counteracting oxidative stress.
3.2. Efficacy of E. longifolia to promote sexual health
Sexual health significantly affects the quality of life of males and females, regardless of socio-economic status, age, gender, and religion. Sexual activity requires an efficient synchronization and integrity between different biological systems (hormones, muscles, neurological pathways, blood circulation etc.) of the body. Sexual dysfunction (inability to perform pleasant sexual activity) negatively affects the quality of life and can be the leading cause of various physical, psychological, and pathologic distresses. In this chain of events, the most prevalent male sexual dysfunctions include premature ejaculation, erectile dysfunction, low testosterone levels and low libido (reduced sexual desire).
To date, numerous in vivo and human clinical studies have explored the therapeutic effectiveness of E. longifolia in the management of various male sexual dysfunctions,,,. The critical analysis of the literature revealed that excellent clinical efficacy of E. longifolia in managing male sexual health is due to its ability to improve hardness and erection of penis, enhance sexual libido, improve male fertility, and escalate testosterone levels,,,.
In recent years, Udani and co-workers conducted a doubleblind and placebo-controlled trial on old males (40–65 years ages) complaining severe erectile dysfunction. The outcomes measured in this study included sexual pleasure, penile erection, erectile hardness, and sexual performance. A remarkable improvement in frequency of sexual intercourse, penile erection and hardness, and overall sexual well-being was observed in males treated with E. longifolia. The improved sexual health in males supplemented with E. longifolia was also explored by Tambi and co-workers. They observed profound improvement in the sexual well-being performance including penile hardness score, sexual intercourse performance, and erectile function.
In another clinical trial, Tambi et al. conducted a placebo-controlled trial on 350 young patients having a history of infertility. They prescribed a daily dose of 200 mg of soluble extract of E. longifolia to all patients. The therapeutic significance of E. longifolia in improving male fertility was evaluated by analyzing concentration of sperms, semen volume, and sperm motility in accordance to World Health Organization (WHO) guidelines (WHO 1999). Male fertility improving efficacy of E. longifolia was also demonstrated by Ismail et al. They conducted randomized placebo-controlled trial on 109 Malay males (ages of 30–55 years) according to the Good Clinical Practice (ICH-6) guidelines and Declaration of Helsinki. A daily dose of 300 mg of E. longifolia was given to all patients. A profound improvement in sexual libido and male fertility was observed.
Despite of its promising efficacy of improving erectile dysfunction, sexual libido, and male fertility, supplementation of E. longifolia has also shown remarkable proficiency to enhance testosterone levels in the body,. Talbott et al. conducted a clinical trial on 63 subjects by supplementing them with daily dose of 200 mg of standardized hot-water extract of E. longifolia for 4 weeks period. As a result, they noticed noticeable improvements in testosterone levels in E. longifolia-treated subjects with subsequent enhancement in sexual activities and well-being. These results were later supported by Henkel et al. They conducted a clinical trial by supplementing 13 subjects (ages of 57–72 years) 400 mg of E. longifolia daily. They observed a significant increase in total free and bound testosterone concentration in all the patients. The increased levels of male sex hormone, in the later phase, produced significant improvement in sexual performance and male sexual libido.
3.3. Anticancer and anti-proliferative activities of E. longifolia
Numerous studies evidenced that the aqueous, methanolic, ethanolic or butanolic extract of E. longifolia and various bioactive compounds isolated from this medicinal plant have shown promising anti-proliferative and cytotoxic effects against various human cancer cell lines including liver carcinoma (HepG2), gastric carcinoma (MGC-803 and BGC-823 cells), intestinal cancers (HT-29 and LOVO cells), malignant melanoma (HM3KO), cervical carcinoma (Hela), human ovarian carcinoma (CaOV-3 and A-2780), breast cancers (MCF-7), and lung carcinoma (A-549 cells).
Eurycomanone, one of the most bioactive medicinal compounds isolated from the extract of E. longifolia, has shown strong anticancer efficacy against various types of human cancers. Wong et al. evaluated the anti-proliferative and anticancer efficacy of the purified eurycomanone on the expression of selected genes of human lung adenocarcinoma (A549 cells) at a concentration range of 5–20 μg/mL. Eurycomanone significantly inhibited the proliferation of human A549 lung adenocarcinoma cells in a dose-dependent manner with lowest cell growth observed at 20 μg/mL. Mahfudh and co-workers evaluated the cytotoxicity of eurycomanone against Hela cells using methylene blue staining assay, Hoechst 33258 nuclear staining, flow cytometry and TUNEL assay. They further investigated the mechanism of cytotoxicity of eurycomanone by examining the protein expression of p53, Bax and Bcl-2 using Western blotting and immunostaining assays. Eurycomanone showed selective cytotoxicity against various cancerous cell lines (MCF-7, HeLa, CaOv-3, HM3KO, and HepG2) but was least toxic against normal human cells (MDBK and Vero cells). The cytotoxicity of eurycomanone is mainly attributed to its ability to induce apoptosis in cancerous cells by inducing chromatin condensation, appearance of apoptotic bodies, and DNA fragmentation in cancerous cells treated with this potent medicinal compound.
Methanolic extract of E. longifolia has also been investigated against human leukemia cells (K-562). In this study, a wide range of in vitro experiments were performed including cell viability, clonogenic assay, annexin V-FITC/PI assay, Hoechst 33342 staining, cell cycle, and RT2 profilerTM PCR array. The anticancer potential of E. longifolia was also evaluated by measuring the tumor volume, inhibition of tumor growth and histological examination using Balb/C nude mice. Their results showed a significant anti-proliferative and growth inhibition activity against K-562 cells treated with various fractions of E. longifolia. Potent cytotoxicity and anti-proliferative effects were observed after 48 h of treatment with half inhibitory concentration (IC50) value of 1 963 and 661 mg/mL, respectively. In this study, authors have also observed a dose-and time-dependent cytotoxicity of K-562 cells at different concentrations of E. longifolia at various time points. They further explored the anti-proliferative and cytotoxicity mechanisms of E. longifolia. By evaluating the biochemical parameters of early apoptosis (Annexin-V positive) and late apoptosis/necrosis (Annexin-V/PI positive), they suggested that treatment of K-562 cells with various fractions of E. longifolia caused induction of apoptosis in a dose-and time-dependent manner. Nuclear changes such as chromatin condensation and DNA fragmentation which are the hallmark features of apoptosis were also identified in K-562 cells treated with E. longifolia (Hoechst 33342 staining). A promising anti-leukemic potential of E. longifolia was also confirmed by an in vivo animal study that showed a remarkable decrease in the tumor volume, number of viable tumor cells, increased numbers of apoptotic cells and the necrotic cells in the E. longifolia (TAF273)-treated mice compared to the control groups. Further analysis of histological micrographs using Image J software revealed a significantly higher percentage of necrosis in E. longifolia (TAF273)-treated group compared to the control group. The mean count of apoptotic cells were 2 566 and 103 611 in the control and TAF273 groups, respectively. These findings suggested that E. longifolia exhibits a strong anti-leukemic potential. E. longifolia has also been used in combination with Dipterocarpus obtusifolius and Tamilnadia uliginosa for the treatment of various types of human cancers.
The standardized quassinoid extract of E. longifolia (SQ40) was also investigated for the treatment of human prostate cancer.
SQ40 is an extract that contains 40% (w/w) of quassinoids was tested for anti-proliferative and anticancer activities against the human prostate cancer using a series of in vitro and in vivo experiments. The cell viability analysis revealed that SQ40 showed a strong dose-dependent cytotoxicity against LNCaP cells (human prostate cancer cell line); however, it showed no cytotoxicity against human normal prostate (RWPE-1) and liver (WRL-68) cells. The concentrations of SQ40 that cause maximal half inhibitory effects (IC50) against RWPE-1, WRL-68 and LNCaP cell lines were 59.26, 27.69, and 5.97 μg/mL, which indicated that SQ40 exhibits potent cytotoxicity against human prostate cancer. The analysis of growth kinetics of LNCaP, RWPE-1 and WRL-68 cells using impedance-based cell sensing measurement system further validated that QS40 showed cytostatic effects at lower concentrations (2.5–10 μg/mL) and cytotoxic response at higher concentrations (20–80 μg/mL). A significant dose-dependent down-regulation of cell cycle regulatory proteins such as CDK4, CDK2, Cyclin D1 and Cyclin D3 and subsequent up-regulation of cell cycle inhibitory protein (p21 Waf1/Kip1) in SQ40-treated LNCaP cells further validated the anti-proliferative and cytotoxic mechanisms of this quassinoid extract against human prostate cancer. The anticancer activity of SQ40 was also evidenced using the in vivo LNCaP tumor xenograft growth in nude mice. An intra-peritoneal administration of SQ40 for a period of 6 weeks in prostate cancer induced nude mice showed a significant dose-dependent decrease in the tumor volume compared to the control groups. These findings evidenced that E. longifolia exhibits strong anticancer potential against human prostate cancer. The potency of quassinoid extract of E. longifolia has also been demonstrated by other researchers. They suggested that the quassinoids from the leave extract of E. longifolia exhibits promising potential against A-549 (human lung cancer cells) and other human cancers.
Several other medicinal compounds of E. longifolia including eurycomanol, 13-β , 21-dihydroxyeurycomanone, 14-hydroxyglaucarubol, eurycomalactone, eurycomadilactone, 5-iso-eurycomadilactone, 13-epi-eurycomadilactone, longilactone, 6-dehyroxylongilactone, canthin-6-one, 9-methoxycanthin-6-one, canthin-6-one 9-O- β -glucopyranoside, 14,15 β -dihydroxyklaineanone, pasakbumin B, and pasakbumin C have also shown strong anti-proliferative and anticancer activities against a wide variety of human cancers in vitro and in vivo,.
The prime mode of cytotoxicity of E. longifolia and its medicinally active compounds in cancerous cells is the induction of apoptosis (programmed cell death) via the up-regulation of the expression of p53 (a tumor suppressor protein) and pro-apoptotic protein (Bax), and the down-regulation of the expression of anti-apoptotic protein (Bcl-2),. However, other studies suggested that activation of caspases (apoptotic signaling cascades) and/or inhibition of NF-к B (nuclear factor kappa-light-chain-enhancer of activated B cells) have also been identified as the important molecular targets of E. longifolia and its medicinal compounds to provoke anti-proliferative and anticancer activities.
3.4. Antibacterial activity of E. longifolia
Being a well-known traditional herbal medicine, plethora of in vitro, in vivo, and human clinical studies have demonstrated a strong antibacterial efficacy of E. longifolia and its bioactive constituents. Phytochemical screening of various types of extracts (methanolic, ethyl acetate, and n-butanolic) from different parts (roots, stem, and leaves) of E. longifolia displayed a dose-dependent antibacterial response against a wide spectrum of Gram positive and Gram negative bacteria. Comparative analysis revealed that the root extract of E. longifolia exhibited highest antimicrobial efficacy in comparison with the other plant parts.
The antibacterial activity of E. longifolia has been evaluated in the form of crude extracts, standardized extracts, and/or various medicinal compounds isolated or extracted from the standardized extracts. Farouk and Benafri evaluated the antibacterial activity of alcoholic and water extracts from the roots, stem, and leaves of E. longifolia against four pathogenic gram negative (Bacillus subtilis, Staphylococcus aureus, Enterococcus feacalis, and Micrococcus leteus) and four gram positive microorganisms (Escherichia coli, Salmonella typhi, Proteus vulgaris, and Serratia marcescens) using the agar well diffusion method. The antibacterial potency of E. longifolia was evaluated in comparison with reference standard antibiotics such as 5 mg/mL tetracycline and 5 mg/mL chloranphenicol. The diameter of inhibition zones were measured after 24 h of incubation. Farouk and Benafri identified that alcoholic root extracts did not show antibacterial activity against all bacterial strains; however, the extracts from the stem and leaves showed significant antibacterial activity against Gram positive bacteria and moderate activity against Gram negative bacteria except Escherichia coli and Salmonella typhi. The aqueous leaf extracts were active against Bacillus subtilis and Serratia marcescens. They concluded that comparatively the leaf extracts showed stronger antibacterial activity than the stem extracts.
In another study conducted by Khanam et al., a dose-dependent antibacterial activity was observed from the root and stem extracts of E. longifolia. In this study, various extracts of methanol, ethyl acetate, acetone, chloroform, and petroleum ether extracts from the stem and root parts of the plant were tested. Resulting data identified that the extract from the stem displayed strongest antibacterial activity against all the strains of bacteria than the root extracts. The highest antibacterial activity [zone inhibition of (17.00±6.56) mm] was observed against Staphylococcus aureus from methanolic extract of stem at a dose of 200 μg/μL. These results indicated that E. longifolia extracts were more active against Gram positive bacteria than the Gram negative bacteria. These results are also in agreement with other studies,. Choo et al. tested n-hexan, chloroform, n-butanol, and aqueous extracts derived from a methanolic-soluble residue of E. longifolia against various pathogenic bacteria (Staphylococcus aureus, Bacillus cereus, Escherichia coli, and Pseudomonas aeruginosa). Results showed that n-hexan and chloroform extracts showed highest antibacterial activity against Bacillus cereus and no activity against Gram negative bacteria. Bioactivity-guided fractionation of chloroform extract resulted in isolation of 9-methoxycanthin-6-one, eurycomalactone, and 14,15 β -dihydroxyklaineanone. Among these three qussinoids, 9-methoxycanthin-6-one displayed strongest antibacterial activity (MIC=9 μg/mL) against Bacillus cereus; however, other two quassinoids did not display antibacterial activity against Bacillus cereus.
Similarly, Los et al. have also identified that E. longifolia extracts exhibited higher antibacterial activity against Gram positive microorganisms than the Gram negative bacteria. They investigated the antibacterial efficacy of aqueous and methanolic extracts of E. longifolia against various strains of Gram positive (Bacillus cereus, Staphylococcus aureus, Bacillus subtilis, Staphylococcus epidermidis, and Micrococcus luteus) and Gram negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumonia, and Proteus mirabilis). Results showed that methanolic extracts showed higher antibacterial activity compared to the aqueous extracts against Gram positive bacteria compared to the Gram negative bacteria at 1 000–2 000 mg/L.
Some other studies revealed that crude extract of E. longifolia exhibited strongest antibacterial activity against Gram negative bacteria than the Gram positive bacteria,. Faisal and co-workers tested ethanol extracts from the roots of E. longifolia against various Gram positive and Gram negative strains of bacteria using agar disc diffusion and broth microdilution test. Though, a dose-dependent increase in antibacterial activity was observed in both Gram negative and Gram positive bacteria; however, greater inhibition zones were observed in Bacillus cereus (11.76 mm) and Salmonella typhi (14.33 mm) at a dose of 150 mg/mL. However, Escherichia coli and Pseudomonas aeruginosa did not show any inhibition by the ethanol extracts.
Some studies suggested a weaker or no antibacterial activity of E. longifolia against Gram positive and Gram negative bacteria,. Tzar and co-workers investigated the antibacterial potential of aqueous extract of E. longifolia against various pathogenic bacteria such as Enterococcus faecium, methicillin-resistant Staphylococcus aureus, group-1 β lactamase-producing Pseudomonas aeruginosa, extended-spectrum β -lactamase-producing Klebsiella pneumoniae, Salmonella typhi, and multidrug-resistant Acinetobacter baumanii) at various doses of 50, 25, 12.5, 6.25, and 3.125 mg/mL. Results indicated that aqueous extract did not showed antibacterial activity at all doses. On the other hand, Jaafar et al. tested antibacterial activity of methanolic extract of E. longifolia, alone or in combination, with Alpinia galanga, and Syzygium aromaticum against Escherichia coli. Results showed that E. longifolia showed weaker antibacterial activity when used alone and moderate activity when used as mixture with Alpinia galanga and Syzygium aromaticum methanolic extracts. These results clearly evidenced a mixed-type antibacterial efficacy of E. longifolia.
3.5. Antiprotozoal activity of E. longifolia
A plethora of in vitro, in vivo and human clinical studies demonstrated an efficient antiprotozoal activity of E. longifolia in the form of crude extracts or isolated bioactive medicinal components against a variety of protozoa including Blastocystis species, Plasmodium falciparum strains, Plasmodium yoelii, and Schistosoma japonicum,.
Blastocystis species are classified as a Stramenopile and genetically diverse organisms that inhabit the intestinal tract of a large range of host species including humans. Among a range of chemotherapeutic agents, metronidazole has become the mainstay in treating Blastocystis induced diseases. However, potential side effects and susceptibility of developing resistance against these pharmacological agents reasoned to search and explore alternative antiprotozoal therapies. Girish et al. tested antiprotozoal activity of aqueous and ethyl acetate extracts of E. longifolia against Blastocystis species derived from human stool samples at two different concentrations of 0.1 and 1.0 mg/mL. They investigated growth profile and viability of Blastocystis species after 72 h of treatment with herbal extracts. Amongst all of the tested herbal extracts, E. longifolia displayed the highest inhibition in growth profile and viability which was achieved at 1.0 mg/mL. Moreover, comparative analysis between aqueous and ethyl acetate fractions revealed that ethyl acetate-based extract showed significantly higher (94.9%–95.1%) antiprotozoal activity against Blastocystis species at 1.0 mg/mL. The antiprotozoal activity of E. longifolia was comparable with metronidazole (95.8%).
Malaria is a mosquito-borne life-threatening blood disease affecting humans and other animals caused by parasitic protozoa (Plasmodium genus). The typical symptoms associated with malaria include consistent tiredness, on and off fever, nausea, vomiting, and headaches. Among various pharmacological interventions, artemisinin is one of the commonly employed anti-malarial agents used in the treatment of malaria. It is mainly derived from a medicinal herb, Artemisia annua. It has displayed promising efficacy against various strains of protozoa; however, some potential side effects (including neurotoxicity) associated with its monotherapy reduced its clinical applicability as antiprotozoal agents. Mohd Ridzuan et al. tested anti-malarial efficacy of standardized root extract (TA164) of E. longifolia, alone and in combination with artemisinin. They administered different doses to Plasmodium yoelii-infected mice via oral and/or subcutaneous routes. Monotherapy of TA164 resulted in a dose-dependent suppression of parasitemia in Plasmodium yoelii-infected mice and highest suppression (approximately 50%) was observed at 60 mg/kg body weight via oral administration. However, combination of TA164 (10 mg/kg body weight) with a fixed dose of artemisinin (1.7 mg/kg body weight) resulted in significantly higher suppression of parasitemia (approximately 63%). Moreover, an increased dose of TA164 (up to 60 mg mg/kg body weight) in conjunction with artemisinin (1.7 mg/kg body weight) resulted in progressive increase in suppression of parasitemia (approximately 80%). Similarly, subcutaneous administration of a combined therapy of TA164 and artemisinin has also resulted in higher suppression of parasitemia compared to the monotherapy of TA164 in infected mice. These findings suggested that combination of E. longifolia with artemisinin can significantly improve antiprotozoal and anti-malarial efficacy of artemisinin.
Bioactivity-guided fractionation revealed that not only crude extract but various isolated medicinal compounds have also shown moderate-to-potent antiprotozoal activity. Successive fractionation of dried and powdered roots of E. longifolia with methanol, chloroform and n-butanol resulted in isolation of various medicinal compounds which were tested against Plasmodium falciparum. Results showed that some of the compounds exhibited moderate antiprotozoal activity; however, others showed strong anti-malarial activity. In another study, Kuo et al. demonstrated that amongst various medicinal compounds isolated from root extracts of E. longifolia, eurycomanone and pasakbumin B showed most potent anti-malarial activity; however, eurycomalactone, 14,15 β -dihydroxyklaineanone, and pasakbumin C exhibited moderate efficacy against Plasmodium falciparum strains.
Eurycomanone, one of the most bioactive medicinal compounds isolated from the root extract of E. longifolia, exhibited outstanding antiplasmodial activity. Chan and co-workers isolated four quassinoids including eurycomanone, 13,21-dihydroeurycomanone, 13α (21)-epoxyeurycomanone, eurycomalactone, and an alkaloid, 9-methoxycanthin-6-one from the root extracts of E. longifolia. The antiprotozoal activity of these compounds was tested against chloroquine-resistant Gombak A isolate of Plasmodium falciparum. Results showed that n-butanol root extracts of E. longifolia exhibited strongest anti-malarial activity (0.34 μg/mL) than its diethyl ether extract (1.50 μg/mL) and both of these extracts were more potent than chloroquine diphosphate (2.50 μg/mL). Bioactivity guided fractionation of n-butanol extract revealed that amongst three of the isolated quassinoids, eurycomanone displayed strongest anti-malarial activity that was approximately 8.66 times more potent than chloroquine diphosphate against the Gombak A isolate compared to 13,21-dihydroeurycomanone (6.83 times potent), and 13,21-epoxyeurycomanone (4.58 times potent).
These results were further validated by Chan et al. in which they demonstrated that amongst several quassinoids isolated from root extract of E. longifolia, eurycomanone displayed strongest inhibition of chloroquine-resistant Gombak A isolate of Plasmodium falciparum. They also suggested that the anti-malarial efficacy of eurycomanone can be modulated by undergoing acylation reaction. Comparative analysis revealed that monoacylated eurycomanones showed comparable activity to eurycomanone; however, diacylated eurycomanones displayed lower antiplasmodial activity against the Gombak A isolates.
3.6. Antifungal activity of E. longifolia
Though, some studies provided substantial evidence regarding the antifungal activity of the crude extract or medicinal compounds isolated from various parts of E. longifolia; however, there is no consensus that which part(s) and type(s) of extract showed the strongest antifungal activity.
Khanam et al. conducted a phytochemical screening of various extracts of methanol, ethyl acetate, acetone, chloroform, and petroleum ether extracts from the stem and root parts of E. longifolia against Aspergillus niger. Comparative analysis revealed that amongst various parts of E. longifolia and a range of extracts, only the ethyl acetate extract from the stem part of E. longifolia exhibited antifungal activity. They identified a dose-dependent antifungal activity of ethyl acetate stem extract with highest zone inhibition [(11.00±1.73) mm] was achieved at 200 μg/μL than a slightly lower antifungal activity [(9.0±1.0) mm] at 100 μg/μL. Another study conducted by Choo et al. suggested that amongst various extracts of E. longifolia, hexane and chloroform extracts exhibited moderate antifungal activity against Candida albicans.
A phytochemical screening of aqueous extracts from the roots of E. longifolia was also conducted by Tzar and co-investigators against Candida albican, Candida glabrata, and Candida krusei at various concentrations (10, 5, 2.5, 1.25 and 0.625 mg/mL). However, the resulting data indicated no activity of aqueous extract against Candida albicans species at any concentration which suggested that E. longifolia did not show antifungal activity at 50 mg/mL or lower concentrations. These results were also validated by Jaafar et al. that E. longifolia extract did not show antifungal activity against Saccharomyces cerevisiae when used alone. However, its combination with Alpinia galanga and Syzygium aromaticum at various ratios of 1:1:1 or 1:2:2 showed promising antifungal activity of (22.4±3.43) mm and (22.6±3.65) mm zone of inhibition, respectively. These findings indicated that ethyl acetate, hexane and chloroform extract of E. longifolia exhibited moderate antifungal activity which evidenced that some parts of E. longifolia should be further screened for antifungal activity.
3.7. Anti-inflammatory activity of E. longifolia
The anti-inflammatory potential of E. longifolia and its bioactive phytochemicals has also been established by many researchers,. Tran and co-workers explored the anti-inflammatory mechanism of E. longifolia and its medicinally active components by bioactivity guided fractionation. They suggested that among various medicinal compounds extracted/isolated from the root extract of E. longifolia, eurycomalactone, 13,21-dehydroeurycomanone, and 14,15 β -dihydroklaieanone showed the most potent anti-inflammatory activity. The anti-inflammatory activity of these phytochemicals is due to their strong efficacy to inhibit NF-κ B. The anti-inflammatory and antioxidant activity of crude extract of E. longifolia was also demonstrated by Varghese et al. They suggested that E. longifolia exhibits a dose-dependent anti-inflammatory and antioxidant activities.
3.8. Anxiolytic effects of E. longifolia
Though, a paucity of data is available for the anxiolytic effects of E. longifolia; however, some studies have explored the anti-anxiety efficacy of various fractions of E. longifolia. Ang and Cheang conducted various behavioral tests in animals supplemented with E. longifolia and the results were compared with control groups. They demonstrated that E. longifolia supplementation significantly reduced the anxiolytic behavior of animals and the results are consistent with diazepam treated animals. Consistently, Talbott et al. conducted a human clinical trial by supplementing 63 subjects with aqueous extract of E. longifolia and screened them for stress hormones and mood states. They noticed a significant improvement in stress hormone and mood state profiles in individuals supplemented with E. longifolia.
3.9. Anti-diabetic effects of E. longifolia
The prevalence of type-2 diabetes is continuously escalating due to increasing insulin resistance. Lowering of lipids accumulation in adipocytes is one of the important ways to improve insulin sensitivity as well as enhance glucose uptake. Recently, Lahrita et al. explored the anti-diabetic efficacy of root extract of E. longifolia. They explored that the anti-diabetic efficacy of E. longifolia was attributed to increased insulin sensitivity and lowered accumulation of lipids in adipocytes. The supplementation of E. longifolia resulted in increased glucose uptake by more than 200% and significant suppression of lipid accumulation at a dose of 50 μg/mL. Moreover, they have also observed no adverse effects of E. longifolia on adipocytes at different doses.
3.10. Miscellaneous effects of E. longifolia
Researchers have also recognized various miscellaneous effects of E. longifolia including ergogenic effects, hormonal effects, muscular effects, and anti-ulcer effects. The supplementation of standardized extract of E. longifolia is associated with profound anti-estrogenic effects, normalizing irregular estrous cycles, and reduced follicular damage associated with chronic testosterone administration,.
E. longifolia and its phytochemicals exhibit a wide dynamic range of biomedical applications including anti-osteoporotic, anticancer, anti-proliferative, anti-malarial, antimicrobial, antioxidant, aphrodisiac, anti-inflammatory, anxiolytic, anti-diabetic, anti-rheumatism and anti-ulcer properties. A critical analysis of the reviewed literature revealed that the promising anti-osteoporotic and bone resorption reducing efficacy of E. longifolia is attributed to its excellent ability to up-regulate the male and female sex hormones (testosterone, androgens, and estrogens). A number of animal and human clinical studies revealed a remarkable potential of E. longifolia and its constituents in improving male and female sexual, which is also attributed to higher testosterone levels following administration of E. longifolia. The anticancer efficacy of E. longifolia is due to the induction of apoptosis (programmed cell death) via the up-regulation of the expression of p53 (tumor suppressor protein) and pro-apoptotic protein (Bax) and down-regulation of the expression of anti-apoptotic protein (Bcl-2). Comparative analysis revealed that the root extract of E. longifolia exhibited highest antimicrobial efficacy in comparison with the other plant parts. Bioactivity-guided fractionation identified that among all of the medicinal compounds isolated/extracted from different parts of E. longifolia, eurycomanone displayed strongest antibacterial, antiprotozoal and antifungal activities.
5. Future prospects
Though plentiful reports have explored the pharmacological significance and therapeutic viability of E. longifolia and its bioactive compounds for the treatment of a variety of diseases, much has yet to be executed and learned. To further explore its biomedical applications, we have noticed substantial gaps in research which include but not limited to; 1) lack of integration of medicinal chemistry, biology, pharmacology and toxicology which could be a promising way to further explore the anticancer specificity of E. longifolia and its compounds against each type of disease, 2) lack of sufficient attention on pharmacologically active constituents and their determination, identification, standardization and structural manipulation for future developments of new structural and functional analogs, 3) lack of research on individual translational mechanism of most active medicinal compounds against various types of diseases, 4) lack of comparative biomedical potential of various active constituents of E. longifolia, 5) lack of sufficient in vivo and human clinical studies to further explore demographic specificity and variations, and 6) lack of sufficient safety profile and toxicity data to conduct human clinical trials.
Conflict of interest statement
The authors declare they have no conflict of interest.
The authors would like to acknowledge Ministry of Agriculture for providing New Application for Herbal Research Grant Scheme (NRGS) (NH1014D040) and supports in writing this review article.
|1||Thu HE, Mohamed IN, Hussain Z, Jayusman PA, Shuid AN. Eurycoma longifolia as a potential adoptogen of male sexual health: A systematic review on clinical studies. Chin J Nat Med 2017; 15(1): 71-80.|
|2||Low BS, Teh CH, Yuen KH, Chan KL. Physicochemical effects of the major quassinoids in a standardized Eurycoma longifolia extract (Fr 2) on the bioavailability and pharmacokinetic properties, and their implications for oral antimalarial activity. Nat Prod Commun 2011; 6: 337-341.|
|3||Farouk AE, Benafri A. Antibacterial activity of Eurycoma longifolia Jack. A Malaysian medicinal plant. Saudi Med J 2007; 28(9): 1422-1424.|
|4||Varghese C, Ambrose C, Jin S, Lim Y, Keisaban T. Antioxidant and anti-inflammatory activity of Eurycoma longifolia Jack. A traditional medicinal plant in Malaysia. Int J Pharm Sci Nanotechnol 2013; 5: 1875-1878.|
|5||Talbott SM, Talbott JA, George A, Pugh M. Effect of tongkat ali on stress hormones and psychological mood state in moderately stressed. J Int Soc Sports Nutr 2013; 10: 28.|
|6||Lahrita L, Kato E, Kawabata J. Uncovering potential of Indonesian medicinal plants on glucose uptake enhancement and lipid suppression in 3T3-L1 adipocytes. J Ethnopharmacol 2015; 168: 229-236.|
|7||Qodriyah H, Asmadi A. Eurycoma longifolia in radix (TM) for the treatment of ethanol-induced gastric lesion in rats. Pak J Biol Sci 2013; 16(23): 1815-1818.|
|8||Tran TVA, Malainer C, Schwaiger S, Atanasov AG, Heiss EH, Dirsch VM, et al. NF-к B Inhibitors from Eurycoma longifolia. J Nat Prod 2014; 77: 483-488.|
|9||Thu HE, Hussain Z, Mohamed IN, Shuid AN. Eurycoma longifolia, a potential phytomedicine for the treatment of cancer: Evidence of p53-mediated apoptosis in cancerous cells. Curr Drug Targets 2017; 18: doi: 1 0.2174/1389450118666170718151913.|
|10||Thu HE, Mohamed IN, Hussain Z, Shuid AN. Eurycoma longifolia as a potential alternative to testosterone for the treatment of osteoporosis: Exploring time-mannered proliferative, differentiative and morphogenic modulation in osteoblasts. J Ethnopharmacol 2017; 195: 143-158.|
|11||Thu HE, Mohamed IN, Hussain Z, Mohamed N, Shuid AN. Eurycoma longifolia, a Malaysian medicinal herb, significantly upregulates proliferation and differentiation in pre-osteoblasts (MC3T3-E1): An in vitro model. Int J Pharm Pharm Sci 2016; 8(11): 199-204.|
|12||Low BS, Ng BH, Choy WP, Yuen KH, Chan KL. Bioavailability and pharmacokinetic studies of eurycomanone from Eurycoma longifolia. Planta Med 2005; 71: 803-807.|
|13||Pan Y, Tiong KH, Abd-Rashid BA, Ismail Z, Ismail R, Mak, JW, et al. Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro. J Nat Med 2014; 68: 402-406.|
|14||Han YM, Kim IS, Rehman SU, Choe K, Yoo HH. In vitro evaluation of the effects of Eurycoma longifolia extract on CYP-mediated drug metabolism. Evid Based Complement Altern Med 2015; 2015: 631329.|
|15||Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 2015; 173(3): R131-151.|
|16||Saadiah Abdul Razak H, Shuid AN, Mohamed IN. Combined effects of Eurycoma longifolia and testosterone on androgen-deficient osteoporosis in a male rat model. Evid Based Complement Altern Med 2012; 2012: 872406.|
|17||Shuid AN, Abu Bakar MF, Abdul Shukor TA, Muhammad N, Mohamed N, Soelaiman IN. The anti-osteoporotic effect of Eurycoma longifolia in aged orchidectomised rat model. Aging Male 2011; 14: 150-154.|
|18||Tambi M, Imran M, Henkel R. Standardised water-soluble extract of Eurycoma longifolia, tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? Andrologia 2012; 44: 226-230.|
|19||Mohamad NV, Soelaiman IN, Chin KY. A concise review of testosterone and bone health. Clin Interv Aging 2016; 11: 1317-1324.|
|20||Banfi G, Iorio EL, Corsi MM. Oxidative stress, free radicals and bone remodeling. Clin Chem Lab Med 2008; 46(11): 1550-1555.|
|21||Mohd Effendy N, Mohamed N, Muhammad N, Mohamad IN, Shuid AN. Eurycoma longifolia: Medicinal plant in the prevention and treatment of male osteoporosis due to androgen deficiency. Evid Based Complement Altern Med 2012; 2012: 125761.|
|22||Tambi M, Imran MK. Eurycoma longifolia Jack in managing idiopathic male infertility. Asian J Androl 2010; 12: 376-380.|
|23||Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, et al. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 2010; 7(4 Pt 2): 1598-1607.|
|24||Tsujimura A. The relationship between testosterone deficiency and men's health. World J Mens Health 2013; 31(2): 126-135.|
|25||Tambi MIBM, Imran MK, Henkel RR. Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism. Andrologia 2012; 44(supp1): 226-230.|
|26||Udani JK, George AA, Musthapa M, Pakdaman MN, Abas A. Effects of a proprietary freeze-dried water extract of Eurycoma longifolia (Physta) and Polygonum minus on sexual performance and well-being in men: a randomized, double-Blind, placebo-controlled study. Evid Based Complement Alternat Med 2014; 2014: 179529.|
|27||George A, Henkel R. Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy. Androlgia 2014; 46(7): 708-721.|
|28||Henkel RR, Wang R, Bassett SH, Chen T, Liu N, Zhu Y, et al. Tongkat ali as a potential herbal supplement for physically active male and female seniors-a pilot study. Phytother Res 2014; 28(4): 544-550.|
|29||Ismail SB, Wan Mohammad WM, George A, Nik Hussain NH, Musthapa Kamal ZM, Liske E. Randomized clinical trial on the use of PHYSTA freeze-dried water extract of Eurycoma longifolia for the improvement of quality of life and sexual well-being in Men. Evid Based Complement Alternat Med 2012; 2012: 429268.|
|30||Wahab NA, Mokhtar NM, Halim WNHA, Das S. The effect of Eurycoma longifolia Jack on spermatogenesis in estrogen-treated rats. Clinics 2010; 65(1): 93-98.|
|31||Tajul AS, Ima Nirwana S, Pramanik J, Shuid AN. Effects of Eurycoma longifolia on testosteron level and bone structure in an aged orchidectomised rat model. Evid Based Complement Alternat Med 2012; 2012: 818072.|
|32||Wong PF, Cheong WF, Shu MH, Teh CH, Chan KL, AbuBakar S. Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28. Phytomedicine 2012; 19: 138-144.|
|33||Mahfudh N, Pihie AHL. Eurycomanone Induces Apoptosis through the Up-regulation of p53 in Human Cervical Carcinoma Cells. J Cancer Mol 2008; 4: 109-115.|
|34||Al-Salahi OSA, Zaki AH, Chan KL, Shah AM, Al-Hassan F, Abdullah WZ, et al. In vitro Anti-proliferative and Apoptotic Activities of Eurycoma longifolia Jack (Simaroubaceae) on HL-60 Cell Line. Trop J Pharm Res 2013; 12: 57-61.|
|35||Lueangamornnara Y, U-pratya W, Jiratchariyakul A, Kulprom A, O-charoenrat P, Kummalue T. Antiproliferative effects of three roots Thai herbal recipe on human cancer cell lines U. Mahidol Univ J Pharm Sci 2017; 44(1): 22-31.|
|36||Tong KL, Chan KL, Abu Bakar S, Low BS, Ma HQ, Wong PF. The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells. PLoS One 2015; 10: e0121752.|
|37||Miyake K, Li F, Tezuka Y, Awale S, Kadota S. Cytotoxic activity of quassinoids from Eurycoma longifolia. Nat Prod Commun 2010; 5(7): 1009-1012.|
|38||Meng D, Li X, Han L, Zhang L, An W, Li X. Four new quassinoids from the roots of Eurycoma longifolia Jack. Fitoterapia 2014; 92: 105-110.|
|39||Park S, Nhiem NX, Van Kiem P, Minh CV, Tai BH, Kim N. Five new quassinoids and cytotoxic constituents from the roots of Eurycoma longifolia. Bioorg Med Chem Lett 2014; 24: 3835-3840.|
|40||Zakaria Y, Rahmat A, Pihie AHL, Abdullah NR, Houghton PJ. Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53. Cancer Cell Int 2009; 9:16.|
|41||Tee TT, Cheah YH, Hawariah LP. F16, a fraction from Eurycoma longifolia jack extract, induces apoptosis via a caspase-9-independent manner in MCF-7 cells. Anticancer Res 2007; 27: 3425-3430.|
|42||Hajjouli S, Chateauvieux S, Teiten MH, Orlikova B, Schumacher M, Dicato M, et al. Eurycomanone and Eurycomanol from Eurycoma longifolia Jack as Regulators of Signaling Pathways Involved in Proliferation, Cell Death and Inflammation. Molecules 2014; 19: 14649-14666.|
|43||Khanam Z, Wen CS, Bhat IUH. Phytochemical screening and antimicrobial activity of root and stem extracts of wild Eurycoma longifolia Jack (Tongkat ali). J King Saud Univ-Sci, 2015; 27(1): 23-30.|
|44||Choo CY, Nah BK, Ibrahim P, Chan KL. Antimicrobial activity of Eurycoma longifolia Jack . Interdisciplinary approaches in natural products research: proceedings of the 16th National Seminar on Natural Products 2014; p. 219-221.|
|45||Los R, Skalicka-Wozniak K, Widelski J, Malm A, Glowniak K. Antimicrobial activity of Eurycoma longifolia and Momordica charantia. Planta Med 2008; 74: PA342.|
|46||Faisal GG, Zakaria SM, Najmuldeen GF. In vitro antibacterial activity of Eurycoma longifolia Jack (Tongkat ali) root extract. Int Med J Malay 2015; 14(1): 77-81|
|47||Danial M, Saghal G, Mubbarakh SA, Sundarasekar J, Subramaniam S. Antibacterial studies on in vivo plant parts of medicinally important Eurycoma longifolia (Tongkat ali). Pak J Bot 2013; 45(5): 1693-1700.|
|48||Tzar M, Hamidah Y, Hartini S, Marianayati M, Nazrun A. The antibacterial or antifungal effects of Eurycoma longifolia root extract. Int J Herbal Plant Med 2010; 2(1): 1-6.|
|49||Jaafar NJ, Ambia KM, Lian HH, Noah RM. The effect of mixture of Alpinia galanga, Eurycoma longifolia Jack and Syzygium aromaticum crude extract on the growth of Saccharomyces cerevisiae and Escherichia coli. J Life Sci 2014; 8(5): 399-403.|
|50||Tran QL, Tezuka Y, Ueda JY, Nguyen NT, Maruyama Y, Begum K. In vitro antiplasmodial activity of antimalarial medicinal plants used in Vietnamese traditional medicine. J Ethnopharmacol 2003; 86: 249-252.|
|51||Girish S, Kumar S, Aminudin N. Tongkat ali (Eurycoma longifolia): A possible therapeutic candidate against Blastocystis sp. Parasit Vectors 2015; 8: 332.|
|52||Stensvold CR. Blastocystis: Genetic diversity and molecular methods for diagnosis and epidemiology. Trop Parasitol 2013; 3: 26-34.|
|53||Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgrad Med J 2005; 81: 71-78.|
|54||Mohd Ridzuan MA, Sow A, Noor Rain A, Mohd Ilham A, Zakiah I. Eurycoma longifolia extract-artemisinin combination: Parasitemia suppression of Plasmodium yoelii-infected mice. Trop Biomed 2007; 24(1): 111-118.|
|55||Kuo PC, Shi LS, Damu AG, Su CR, Huang CH. Ke CH, et al. Cytotoxic and antimalarial-carboline alkaloids from the roots of Eurycoma longifolia. J Nat Prod 2003; 66, 1324-1327.|
|56||Kuo PC, Damu AG, Lee KH, Wu TS. Cytotoxic and antimalarial constituents from the roots of Eurycoma longifolia. Bioorg Med Chem 2004; 12(3): 537-544.|
|57||Chan KL, Choo CY, Abdullah NR, Ismail Z. Antiplasmodial studies of Eurycoma longifolia Jack using the lactate dehydrogenase assay of Plasmodium falciparum. J Ethnopharmacol 2004; 92: 223-227.|
|58||Chan KL, Choo CY, Abdullah NR. Semisynthetic 15-O-acyl-and 1,15-di-O-acyleurycomanones from Eurycoma longifolia as potential antimalarials. Planta Med 2005; 71(10): 967-969.|
|59||Ang HH, Cheang HS. Studies on the anxiolytic activity of Eurycoma longifolia Jack roots in mice. Jpn J Pharmacol 1999; 79: 497-500.|
|60||Teh CH, Abdulghani M, Morita H, Shiro M, Hussin AH, Chan KL. Comparative X-ray and conformational analysis of a new crystal of 13,21-dihydroeurycomanone with eurycomanone from Eurycoma longifolia and their anti-estrogenic activity using the uterotrophic assay. Planta Med 2011; 77: 128-132.|
|61||Abdulghani M, Hussin AH, Sulaiman SA, Chan KL. The ameliorative effects of Eurycoma longifolia Jack on testosterone-induced reproductive disorders in female rats. Reprod Biol 2012; 12: 247-255.|
|62||Ulbricht C, Conquer J, Flanagan K, Isaac R, Rusie E, Windsor RC. An evidence-based systematic review of tongkat ali (Eurycoma longifolia) by the natural standard research collaboration. J Diet Suppl 2013; 10: 54-83.|